Kimberly J. Van Zee, MS, MD, FACS, attending surgeon at Memorial Sloan Kettering Cancer Center, discusses the institution's ...

Kimberly J. Van Zee, MS, MD, FACS, attending surgeon at Memorial Sloan Kettering Cancer Center, discusses the institution's ...

The study's findings have implications for early detection and prevention of breast cancer, suggesting that chromosomal ...

The FDA has granted approval for the use of encorafenib in combination with cetuximab and mFOLFOX6 for the treatment of ...

Treatment sequencing with targeted therapies may help to improve overall survival, according to real-world data.

Panelists discuss how adverse event profiles, management strategies, and patient education approaches differ among EGFR-targeted therapies for non–small cell lung cancer, including oral tyrosine ...

Medical experts discuss strategies for patient education on managing potential adverse events of lorlatinib and other ALK inhibitors, emphasizing what to expect and when to contact the care team.

Panelists discuss how the availability of subcutaneous amivantamab influences nursing approaches to patient care and education, with Squires sharing strategies for ensuring patients understand the new ...

Kimberly J. Van Zee, MS, MD, FACS, attending surgeon at Memorial Sloan Kettering Cancer Center, discusses the institution's newly-developed nomogram that can help women make treatment decisions about ...

Kimberly J. Van Zee, MS, MD, FACS, attending surgeon at Memorial Sloan Kettering Cancer Center, discusses the institution's newly-developed nomogram that can help women make treatment decisions about ...

Profiling a 58-year-old retired construction manager with Stage IV EGFR+ NSCLC, discussing his transition from osimertinib to amivantamab plus chemotherapy, managing side effects, and maintaining hope ...

Medical experts discuss strategies for educating patients on managing side effects of osimertinib and other EGFR inhibitors, with guidance on recognizing symptoms that warrant contacting their care ...